PMID- 26330284 OWN - NLM STAT- MEDLINE VI - 9 IP - 9 TI - Mass spectrometry imaging tools in oncology. PG - 863-8 LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - England TA - Biomark Med JT - Biomarkers in medicine JID - 101312535 IS - 1752-0371 (Electronic) LID - 10.2217/bmm.15.61 [doi] FAU - Cole, Laura M AU - Cole LM AD - Biomolecular Sciences Research Centre, Sheffield Hallam University, Howard Street, Sheffield, S1 1WB, UK. FAU - Clench, Malcolm R AU - Clench MR AD - Biomolecular Sciences Research Centre, Sheffield Hallam University, Howard Street, Sheffield, S1 1WB, UK. IS - 1752-0363 (Linking) SB - IM MH - Humans MH - Mass Spectrometry/*methods MH - Molecular Imaging/*methods MH - *Neoplasms/metabolism/pathology MH - Tissue Array Analysis OTO - NOTNLM OT - MALDI source OT - ion mobility separation (IMS) OT - matrix OT - matrix cocrystallization OT - spatial resolution DCOM- 20160706 LR - 20200306 DP - 2015 DEP - 20150902 AB - MS imaging allows profiling and imaging of compounds directly from tumor tissue, tissue microarrays and tissue-engineered models of tumors. Methodologies for the quantitative analysis of localized/colocalized ion signals from a single cancer cell would be a major advance. Alternative methods of generating ions to matrix-assisted laser desorption ionization are increasingly employed. Desorption electrospray ionization has been used for the intraoperative diagnosis of human brain tumors and secondary ion MS imaging with cluster primary ion sources has been used for high spatial resolution imaging tumor sections. Extensive validation of the technique for the analysis of disease biomarkers is required, if imaging MS is to have a future role in the clinic.